DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Loading...
Embargo End Date
Authors
Petkar, I
Rooney, K
Roe, JWG
Patterson, JM
Bernstein, D
Tyler, JM
Emson, MA
Morden, JP
Mertens, K
Miles, E
Beasley, M
Roques, T
Bhide, SA
Newbold, KL
Harrington, KJ
Hall, E
Nutting, CM
Rooney, K
Roe, JWG
Patterson, JM
Bernstein, D
Tyler, JM
Emson, MA
Morden, JP
Mertens, K
Miles, E
Beasley, M
Roques, T
Bhide, SA
Newbold, KL
Harrington, KJ
Hall, E
Nutting, CM
Document Type
Journal Article
Date
2016-10-06
Date Accepted
2016-09-26
Abstract
BACKGROUND: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of critical swallowing structures such as the pharyngeal constrictor muscle and supraglottic larynx can translate to better functional outcomes. However, there are no current randomised studies to confirm the benefits of such swallow sparing strategies. The aim of Dysphagia/Aspiration at risk structures (DARS) trial is to determine whether reducing the dose to the pharyngeal constrictors with dysphagia-optimised intensity- modulated radiotherapy (Do-IMRT) will lead to an improvement in long- term swallowing function without having any detrimental impact on disease-specific survival outcomes. METHODS/DESIGN: The DARS trial (CRUK/14/014) is a phase III multicentre randomised controlled trial (RCT) for patients undergoing primary (chemo) radiotherapy for T1-4, N0-3, M0 pharyngeal cancers. Patients will be randomised (1:1 ratio) to either standard IMRT (S-IMRT) or Do-IMRT. Radiotherapy doses will be the same in both groups; however in patients allocated to Do-IMRT, irradiation of the pharyngeal musculature will be reduced by delivering IMRT identifying the pharyngeal muscles as organs at risk. The primary endpoint of the trial is the difference in the mean MD Anderson Dysphagia Inventory (MDADI) composite score, a patient-reported outcome, measured at 12 months post radiotherapy. Secondary endpoints include prospective and longitudinal evaluation of swallow outcomes incorporating a range of subjective and objective assessments, quality of life measures, loco-regional control and overall survival. Patients and speech and language therapists (SLTs) will both be blinded to treatment allocation arm to minimise outcome-reporting bias. DISCUSSION: DARS is the first RCT investigating the effect of swallow sparing strategies on improving long-term swallowing outcomes in pharyngeal cancers. An integral part of the study is the multidimensional approach to swallowing assessment, providing robust data for the standardisation of future swallow outcome measures. A translational sub- study, which may lead to the development of future predictive and prognostic biomarkers, is also planned. TRIAL REGISTRATION: This study is registered with the International Standard Randomised Controlled Trial register, ISRCTN25458988 (04/01/2016).
Citation
BMC cancer, 2016, 16 (1), pp. 770 - ?
Source Title
Publisher
BMC
ISSN
1471-2407
eISSN
1471-2407
Research Team
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Radiotherapy Physics Modelling
Targeted Therapy
ICR-CTSU Urology and Head and Neck Trials Team
Radiotherapy Physics Modelling
Targeted Therapy